- Home
- DHR vs AMGN Comparison
DHR vs AMGN Comparison
Compare DHR & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHR
- AMGN
- Stock Information
- Founded
- DHR 1969
- AMGN 1980
- Country
- DHR United States
- AMGN United States
- Employees
- DHR N/A
- AMGN N/A
- Industry
- DHR Industrial Machinery/Components
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHR Industrials
- AMGN Health Care
- Exchange
- DHR Nasdaq
- AMGN Nasdaq
- Market Cap
- DHR 160.2B
- AMGN 156.2B
- IPO Year
- DHR N/A
- AMGN N/A
- Fundamental
- Price
- DHR $186.83
- AMGN $277.29
- Analyst Decision
- DHR Buy
- AMGN Buy
- Analyst Count
- DHR 18
- AMGN 20
- Target Price
- DHR $274.00
- AMGN $324.32
- AVG Volume (30 Days)
- DHR 4.6M
- AMGN 3.7M
- Earning Date
- DHR 04-22-2025
- AMGN 05-01-2025
- Dividend Yield
- DHR 0.67%
- AMGN 3.43%
- EPS Growth
- DHR N/A
- AMGN N/A
- EPS
- DHR 5.29
- AMGN 7.56
- Revenue
- DHR $23,875,000,000.00
- AMGN $33,424,000,000.00
- Revenue This Year
- DHR $2.18
- AMGN $7.36
- Revenue Next Year
- DHR $6.81
- AMGN $2.30
- P/E Ratio
- DHR $35.32
- AMGN $36.68
- Revenue Growth
- DHR N/A
- AMGN 18.57
- 52 Week Low
- DHR $171.00
- AMGN $253.30
- 52 Week High
- DHR $281.70
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- DHR 41.61
- AMGN 36.23
- Support Level
- DHR $188.56
- AMGN $267.40
- Resistance Level
- DHR $195.95
- AMGN $296.17
- Average True Range (ATR)
- DHR 10.05
- AMGN 12.41
- MACD
- DHR -0.03
- AMGN -2.02
- Stochastic Oscillator
- DHR 45.06
- AMGN 20.78
About DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.